Mash, D.C. (2023). IUPHAR – invited review – Ibogaine – A legacy within the current renaissance of psychedelic therapy. Pharmacological Research, 190, 106620. https://doi.org/10.1016/j.phrs.2022.106620.

Mash DC, Duque L, Page B, Ferdinand KA Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: Clinical observations and treatment outcomes.  Frontiers Psychopharmacology published: 05 June 2018 doi: 10.3389/fphar.2018.00529

Am J Drug Alcohol Abuse. 2018;44(1):1-3. doi: 10.1080/00952990.2017.1357184. Epub 2017

Mash DC Breaking the cycle of opioid use disorder with Ibogaine.

Mash DC, Ameer B, Prou D, Howes JF, Maillet EL Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents. J Psychopharmacol. 2016 Jul; 30(7):688-97. doi: 10.1177/0269881116641331. Epub 2016 Apr 4. PMID: 27044509

Maillet EL, Milon N, Heghinian MD, Fishback J, Schurer SC, Garamszegi N, Mash DC. Noribogaine is a G-protein  biased k-opioid receptor agonist. Neuropharmacology. 2015 Dec; 99:675-88. DOI: 10.1016.

Maillet E, Chang Q, Milon N, Hanania T, Heghinian M, Garamszegi N, Mash DC. Characterization of Noribogaine at nAChRs and Effect on Nicotine Self-Administration in Rats. J. Psychopharmacol. (6): 704-11. DOI: 1019.2. 2015.

Chang Q, Hanania T, Mash DC, Maillet E. Noribogaine reduces nicotine self-administration in rats. J  Psychoparmacol. 29(6): 704-711. DOI: 10.1177/026988115584461. 2015.

Mash DC. Ibogaine therapy for substance abuse disorders: Clinical Addition Psychiatry: (Part 1, Chapter 6). Editors: Brizer, D. and Castaneda, R., Cambridge University Press, 2010.

Passarella, D., Barilli, A., Efange, S.M.N., Elisabetsky, E., Leal, M.B., Lesma, G., Linck, V.M., Mash, D.C., Martinelli, M., Peretto, H., Silvani, A., Danieli, B. Nature-inspired indolyl-2-azabicyclo [2.2.2] act-7-ene derivatives as promising agents for the attention of withdrawal symptoms. Synthesis of 20-desethyl-20-hydroxymethyl-11-demethoxyibogaine. Nat Prod Res 20(8):758-65, 2006.

Mash, D.C. Ibogaine Therapy. Euro Neuropsychopharm 15(3):S322, 2005.

Pasarella, D., Favia, R., Giardini, A., Lessma, G., Martinelli, M., Silvani, A., Danieli, B., Efange, S.M.N., and Mash, D.C. Ibogaine analogues. Synthesis and preliminary pharmacological evaluation of 7-heteroaryl-2-azabicyclo [2.2.2] Oct-7-enes. Biorg. Med. Chem. 11(6):1007-14, 2003.

Baumann, M.H., Pablo, J., Ali, S.F., Rothman, R.B., Mash, D.C. Comparative neuropathology of ibogaine and its o-desmethyl metabolite, noribogaine. In: Ibogaine: Proceeding of the First International Conference., Alkaloid Series, Volume 56.  Editors: Dr. Kenneth Alper and Dr. Stan Glick. Academic Press, San Diego, California pp 80-109, 2001.

Mash, D.C., Kovera, C.A., Pablo, J., Tyndale, R., Ervin, F.R., Kamlet, J.D., Hearn, W. L. Ibogaine in the treatment of heroin withdrawal. In: Ibogaine: Proceeding of the first International Conference., Alkaloid Series, Volume 56. Editors: Dr. Kenneth Alper and Dr. Stan Glick. Academic Press, San Diego, California pp 156-170, 2001.

Baumann, M.H., Rothman, R.B., Pablo, J.P., Mash, D.C. In vivo neurobiological effects of ibogaine and its o-Des-methyl metabolite, 12-hydroxyibogamine (Noribogaine), in rats. J. Pharm. Exp. Ther. 297(2):531-539, 2001.

Mash, D.C., Kovera, C.A., Pablo, J., Tyndale, F.R., Ervin, F.D., Williams, I.C., Singelton, E.G., Mayor, Manny. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.  Ann New York Acad Science, 914:394-401, 2000.

Zubaran, C., Shoaib, M., Stolerman, I.P., Pablo, J., Mash, D.C., Noribogaine generalization to the ibogaine stimulus: Correlation with noribogaine concentration in rat brain. Neuropsychopharmacology 21: 119-126, 1999.

Mash, D.C., Kovera, C. A., Buck, B.E., Norenberg, M.E., Shapshak, P., Hearn, W.L. and Sanchez-Ramos, J. Medication development of Ibogaine as a pharmacotherapy for drug dependence,  (ed. Sayed Ali),  Ann. New York Academy of Sciences, 844:274-292, 1998.

Obach, R. S., Pablo, J. and Mash, D.C. Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metabolism and Disposition 25(12):1359-69, 1998.

Pablo, J. and Mash, D.C. Noribogaine stimulates naloxone-sensitive [35S]GTPgS binding. NeuroReport 9:109-114, 1998.

Efange, S.M.N., Mash, D.C., Khare, A.B., Ouyang, Q. Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5,6 hexahydroazepino [4,5-b] benzothiophenes.  J. Med. Chem. 41(23):4486-91, 1998.

Sanchez-Ramos, J. and Mash, D. C. Pharmacotherapy of drug dependence with Ibogaine, IN: Constructive Potential of Psychedelics: Cross-Cultural Perspectives, (Winkelman, M., and Andritzky, W., eds.) Yearbook of Cross-Cultural Medicine and Psychotherapy, Berlin, pp. 353- 367, 1996.

Staley, J.K., Ouyang, Q, Pablo, J., Hearn , W.L., Flynn, D.D., Rothman, R.B.,  Rice, K.C. Mash, D.C., Pharmacological screen for activities of 12-hydroxyibogamine: A primary metabolite of the indole alkaloid ibogaine. Psychopharm 127:10-18, 1996.

Mash, D.C., Douyan, R., Hearn, W.L., Sambol, N.C., Sanchez-Ramos, J.  A preliminary report on the safety and pharmacokinetics of ibogaine. Biol. Psych.  37: 652, 1995.

Hearn, W.L., Pablo, J., Hime, G. and Mash, D.C. Identification and quantitation of ibogaine and an o-demethylated metabolite in brain and biological fluids using gas chromatography/mass spectrometry. J. Anal. Tox. 19:427-434, 1995.

Mash, D.C., Pablo, J., Staley, J. K., Holohean, A.M., Hackman, J.C., and Davidoff, R.A., Properties of Ibogaine and a principal metabolite (12-Hydroxyibogamine) at the MK-801 binding site on the NMDA- receptor complex. Neurosci. Letters 192:53-56, 1995.

Mash, D.C., Staley, J.K., Baumann, M., Rothman, R.P., and Hearn, W.L., Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Pharmacol. Letters 57: 45-50, 1995.

Hearn, W. L., Mash, D.C., Pablo, J., Hime, G., Sambol, N.C., and Doepel, F.M. Pharmacokinetics of Ibogaine: Analytical method, animal-human comparisons, and the identification of a primary metabolite. Proceedings of the TIAFT-SOFT Joint Congress, Oct. 21 – Nov. 4, 1994 (Spiehler, V. ed.) Omnipress, Ann Arbor, MI, pp. 325 – 334, 1995.